BR112014002141A2 - crizotinib para uso no tratamento de câncer - Google Patents
crizotinib para uso no tratamento de câncerInfo
- Publication number
- BR112014002141A2 BR112014002141A2 BR112014002141A BR112014002141A BR112014002141A2 BR 112014002141 A2 BR112014002141 A2 BR 112014002141A2 BR 112014002141 A BR112014002141 A BR 112014002141A BR 112014002141 A BR112014002141 A BR 112014002141A BR 112014002141 A2 BR112014002141 A2 BR 112014002141A2
- Authority
- BR
- Brazil
- Prior art keywords
- crizotinib
- cancer treatment
- cancer
- treatment
- provides methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo patente de invenção: "crizotinib para uso no tratamento de câncer". a presente invenção refere-se à utilização de inibidores de ros quinase para o tratamento de crescimento de célula anormal em mamíferos. em particular, a invenção proporciona métodos de tratamento de mamíferos que sofrem de câncer mediado por, pelo menos, um ros geneticamente alterado. em particular, a invenção proporciona métodos de tratamento de mamíferos que sofrem de câncer mediado por, pelo menos, um ros geneticamente alterado pela administração de crizotinib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161514386P | 2011-08-02 | 2011-08-02 | |
PCT/IB2012/053765 WO2013017989A1 (en) | 2011-08-02 | 2012-07-24 | Crizotinib for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014002141A2 true BR112014002141A2 (pt) | 2017-02-21 |
Family
ID=46845786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014002141A BR112014002141A2 (pt) | 2011-08-02 | 2012-07-24 | crizotinib para uso no tratamento de câncer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160206608A1 (pt) |
EP (1) | EP2739284A1 (pt) |
JP (1) | JP2013032355A (pt) |
KR (1) | KR20140041906A (pt) |
CN (1) | CN103841972A (pt) |
AR (1) | AR087731A1 (pt) |
AU (1) | AU2012291744A1 (pt) |
BR (1) | BR112014002141A2 (pt) |
CA (1) | CA2842493A1 (pt) |
HK (1) | HK1198133A1 (pt) |
IL (1) | IL230698A0 (pt) |
MX (1) | MX2014001354A (pt) |
RU (1) | RU2014102935A (pt) |
TW (1) | TW201313698A (pt) |
WO (1) | WO2013017989A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
CA2744236C (en) | 2009-02-12 | 2021-03-16 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
AU2013268400B2 (en) | 2012-05-30 | 2017-07-13 | Nippon Shinyaku Co., Ltd. | Aromatic heterocyclic derivative and pharmaceutical |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
ITMI20131124A1 (it) | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
KR101538385B1 (ko) * | 2013-09-02 | 2015-07-29 | 가톨릭대학교 산학협력단 | 크리조티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
WO2015144799A1 (en) * | 2014-03-27 | 2015-10-01 | Janssen Pharmaceutica Nv | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
WO2017058780A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
US20220033402A1 (en) * | 2018-09-27 | 2022-02-03 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of alk, trka, trkb, and ros1 |
KR20210100557A (ko) | 2020-02-06 | 2021-08-17 | 웰마커바이오 주식회사 | Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물 |
EP4115887A1 (en) | 2020-03-03 | 2023-01-11 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
CN113493437B (zh) * | 2020-04-03 | 2022-07-26 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法和用途 |
WO2021196655A1 (zh) * | 2020-04-03 | 2021-10-07 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法与用途 |
CN111518769A (zh) * | 2020-05-13 | 2020-08-11 | 四川大学华西医院 | 一种克唑替尼获得性耐药肺腺癌细胞系的建立方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
DK1603570T5 (da) | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
ME01309B (me) * | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
JP4242911B2 (ja) | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
EP3360965A1 (en) | 2006-01-20 | 2018-08-15 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
CA2744236C (en) | 2009-02-12 | 2021-03-16 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
-
2012
- 2012-07-24 MX MX2014001354A patent/MX2014001354A/es unknown
- 2012-07-24 EP EP12758893.7A patent/EP2739284A1/en not_active Withdrawn
- 2012-07-24 CA CA2842493A patent/CA2842493A1/en not_active Abandoned
- 2012-07-24 RU RU2014102935/15A patent/RU2014102935A/ru not_active Application Discontinuation
- 2012-07-24 US US14/236,034 patent/US20160206608A1/en not_active Abandoned
- 2012-07-24 BR BR112014002141A patent/BR112014002141A2/pt not_active IP Right Cessation
- 2012-07-24 KR KR1020147005056A patent/KR20140041906A/ko not_active Application Discontinuation
- 2012-07-24 AU AU2012291744A patent/AU2012291744A1/en not_active Abandoned
- 2012-07-24 WO PCT/IB2012/053765 patent/WO2013017989A1/en active Application Filing
- 2012-07-24 CN CN201280038393.4A patent/CN103841972A/zh active Pending
- 2012-07-26 JP JP2012165368A patent/JP2013032355A/ja not_active Withdrawn
- 2012-08-01 TW TW101127848A patent/TW201313698A/zh unknown
- 2012-08-01 AR ARP120102813A patent/AR087731A1/es unknown
-
2014
- 2014-01-28 IL IL230698A patent/IL230698A0/en unknown
- 2014-11-19 HK HK14111675.3A patent/HK1198133A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2739284A1 (en) | 2014-06-11 |
TW201313698A (zh) | 2013-04-01 |
CN103841972A (zh) | 2014-06-04 |
KR20140041906A (ko) | 2014-04-04 |
AR087731A1 (es) | 2014-04-16 |
US20160206608A1 (en) | 2016-07-21 |
MX2014001354A (es) | 2014-10-14 |
JP2013032355A (ja) | 2013-02-14 |
HK1198133A1 (en) | 2015-03-13 |
AU2012291744A1 (en) | 2014-02-20 |
CA2842493A1 (en) | 2013-02-07 |
WO2013017989A1 (en) | 2013-02-07 |
IL230698A0 (en) | 2014-03-31 |
RU2014102935A (ru) | 2015-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
MX2016001037A (es) | Inhibidores de factores de transcripción y usos. | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
IN2015DN01156A (pt) | ||
WO2013024282A3 (en) | Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer | |
BR112015012987A2 (pt) | composições compreendendo anticorpos anti-cd38 e lenalidomida | |
PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
BR112014001600A2 (pt) | composto inibidor do trajeto de sinalização notch | |
MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
BR112015005369A2 (pt) | inibidores de usp30 e métodos para sua utilização | |
BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
NZ748769A (en) | Nitroxyl donors with improved therapeutic index | |
BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
FR2973031B1 (fr) | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
BR112014011453A2 (pt) | n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica | |
BR112014004224A2 (pt) | aparelhos e métodos para tratamento de estacas de caules de cana-de açúcar | |
BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina | |
MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |